Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history

Computed tomography features of recurrent ovarian carcinoma according to time to relapse

“…A weakness of this study is that there is no reference standard against which CT findings can be tested: biopsy was not performed in all cases, and standard treatment for relapse is chemotherapy rather than surgery. Nonetheless, CT findings are well described, and we are therefore confident that our findings represent relapsed ovarian carcinoma (7). Although FDG-PET has been advocated for the surveillance and detection of recurrent ovarian cancer, this is not routine in our institution (18,19).…”

Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

“…[8][9][10] And the sensitivity and specificity of PET-CT are 93.3-97.4% and 80-100%, respectively. [11,12] A recent meta-analysis of 29 studies demonstrated that PET-CT had high sensitivity (89%) and specificity (90%).…”

Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 Levels

“…In the setting of elevated tumor markers, CECT provides highresolution measurable information on the extent of disease and the anatomic sites of involvement, 26 and the measurement of lesion size is possible, 27 although sometimes, CECT cannot easily differentiate postoperative changes from tumor relapse. By contrast, FDG-PET/CT can detect metabolically active disease, improve the specificity for detection of tumor recurrence, and can define the anatomic sites of suspected recurrence.…”